| Optimizing the use of next-generation sequencing assays in patients with urothelial carcinoma: recommendations by the 2023 San Raffaele Retreat panel V Tateo, A Cigliola, C Mercinelli, N Agarwal, P Grivas, AM Kamat, EA Gibb, ... Clinical Genitourinary Cancer 22 (4), 102091, 2024 | | 2024 |
| Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the … K Takemura, T Yuasa, A Lemelin, E Ferrier, JC Wells, E Saad, RM Saliby, ... ESMO Open 9 (7), 103606, 2024 | | 2024 |
| Effect of Concomitant Medications on Treatment Response and Survival in Non-Metastatic Castrate Resistant Prostate Cancer: Exploratory Analysis of the SPARTAN trial S Roy, F Saad, Y Sun, S Malone, DE Spratt, AU Kishan, CJD Wallis, ... European Journal of Cancer, 114197, 2024 | | 2024 |
| Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor+ Novel … ND Shore, MS Broder, PC Barata, T Crispino, AP Fay, J Lloyd, B Mellado, ... European Urology Oncology, 2024 | | 2024 |
| Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis N Tripathi, G Gebrael, B Chigarira, KK Sahu, I Balasubramanian, ... Cancers 16 (11), 2143, 2024 | | 2024 |
| A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 N Agarwal, D Castellano, T Alonso-Gordoa, JA Arranz Arija, E Colomba, ... Clinical Cancer Research 30 (11), 2377-2383, 2024 | | 2024 |
| Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09) NM Tannir, MN Formiga, K Penkov, N Kislov, A Vasiliev, N Gunnar Skare, ... Journal of Clinical Oncology, JCO. 23.02082, 2024 | | 2024 |
| Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database. RR McKay, C Jani, E Tran, AJ Hockenberry, EB Jaeger, N Husni, ... Journal of Clinical Oncology 42 (16_suppl), 4533-4533, 2024 | | 2024 |
| Resources to address challenges in first-line treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC): A discrete choice experiment. S Loeb, N Agarwal, NN El-Chaar, L de Ruiter, J Kim, J Mack, CS Bland, ... Journal of Clinical Oncology 42 (16_suppl), 5087-5087, 2024 | | 2024 |
| Impact of alterations in tumor suppressor genes (TSG-alt) on survival outcomes in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC … A Narang, RP Graf, G Gebrael, C Hage Chehade, G Li, ZI Ozay, ... Journal of Clinical Oncology 42 (16_suppl), 5091-5091, 2024 | | 2024 |
| Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA)+ enzalutamide (ENZA) vs … S Yip, K Fizazi, D Laird, N Matsubara, A Azad, JY Joung, PCC Fong, ... Journal of Clinical Oncology 42 (16_suppl), 5023-5023, 2024 | | 2024 |
| Changes in treatment (Rx) patterns and attrition rates in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). G Galarza Fortuna, Y Jo, C Hage Chehade, A Narang, G Gebrael, ... Journal of Clinical Oncology 42 (16_suppl), 4527-4527, 2024 | 1 | 2024 |
| A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant … MJ Morris, JYC Wong, L Nordquist, RZ Szmulewitz, N Agarwal, EF Attiyeh, ... Journal of Clinical Oncology 42 (16_suppl), 5010-5010, 2024 | | 2024 |
| FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study. M Basin, RA Sager, D Pavlick, A Necchi, PE Spiess, R Li, AM Kamat, ... Journal of Clinical Oncology 42 (16_suppl), 4588-4588, 2024 | | 2024 |
| Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA)+ enzalutamide (ENZA) vs placebo (PBO)+ ENZA as first-line (1L … A Azad, K Fizazi, D Laird, N Matsubara, U De Giorgi, C ButtIgliero, ... Journal of Clinical Oncology 42 (16_suppl), 5020-5020, 2024 | | 2024 |
| Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study. MB Atkins, P Ghatalia, JR Merchan, S George, J Haanen, H Gurney, ... Journal of Clinical Oncology 42 (16_suppl), 4534-4534, 2024 | | 2024 |
| Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC). RR McKay, S Nazari, A Elliott, BS Rose, PC Barata, D Kilari, R Garje, ... Journal of Clinical Oncology 42 (16_suppl), 5051-5051, 2024 | | 2024 |
| Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data … U Swami, Y Jo, A Narang, M Plets, C Hage Chehade, G Gebrael, S Gupta, ... Journal of Clinical Oncology 42 (16_suppl), 5081-5081, 2024 | | 2024 |
| CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer. MR Smith, JM Piulats, T Todenhöfer, JL Lee, JA Arranz Arija, L Mazilu, ... Journal of Clinical Oncology 42 (16_suppl), 5001-5001, 2024 | | 2024 |
| Clinical and genomic landscape of neuroendocrine prostate cancer (NEC) vs. prostate adenocarcinoma (AdenoK). G Gebrael, M Ostrowski, J Williams, C Hage Chehade, A Narang, ZI Ozay, ... Journal of Clinical Oncology 42 (16_suppl), 5026-5026, 2024 | | 2024 |
